GSK to buy Nuvalent for $10.6B, boosting lung cancer drug pipeline and sales growth from 2027

GSK has agreed to acquire US biotech firm Nuvalent for $10.6 billion (£8 billion) to enhance its oncology portfolio with advanced lung cancer treatments and other assets. The deal includes late-stage drugs zidesamtinib and neladalkib, both under FDA review, expected to launch this year if approved. GSK expects the acquisition to drive revenue growth from 2027 and increase profits and earnings per share by 2029. The company will pay a 40% premium, valuing Nuvalent shares at $124 each in cash.